MOTS-C, the Mitochondrial-Derived Peptide: What Research Has Examined

Educational content only. Not medical advice. FeelGood does not claim that any peptide treats, cures, prevents, or mitigates any disease or condition. Consult a qualified healthcare provider before making any decisions about peptide therapy.

MOTS-C is a 16 amino acid mitochondrial-derived peptide first reported in 2015. Preclinical research, largely in cell and animal models, has examined its proposed role in cellular metabolism through the AMPK pathway, exercise-associated metabolic signaling, and age-related decline. Human data are limited to an analog studied in early-phase trials, and MOTS-C is not an approved drug.[1]

MOTS-C is a mitochondrial-derived peptide (MDP) of 16 amino acids, encoded by a short open reading frame within the 12S ribosomal RNA region (the MT-RNR1 gene) of mitochondrial DNA rather than the nuclear genome.[1] Its reported amino-acid sequence is MRWQEMGYIFYPRKLR.[2] It belongs to a small family of peptides translated from the mitochondrial genome, of which humanin was the first to be described.[1]

The compound has drawn attention in the popular press under labels such as "exercise in a vial" and similar performance and longevity framings. The published record is narrower and more specific than those labels suggest. Most of what has been reported about MOTS-C comes from cell culture and rodent experiments, and the findings are framed by their authors as observations in those models. This article summarizes what specific studies examined, in which systems, and where the human evidence stands.

Discovery and the foundational literature

MOTS-C was identified by Changhan Lee, Pinchas Cohen, and colleagues at the University of Southern California and reported in Cell Metabolism in 2015.[1] The work emerged from the Cohen laboratory's earlier interest in peptides encoded within mitochondrial DNA. Before this, humanin was, in the authors' words, the only reported mitochondrial-derived peptide whose short open reading frame mapped to the mitochondrial genome.[1]

The 2015 paper characterized MOTS-C as a peptide translated from a sequence inside the 12S rRNA region and reported that it could be detected in cells, in mouse tissue, and in circulation.[1] That detection in plasma is part of why later authors describe MOTS-C as a candidate signaling molecule rather than a purely intracellular product. The discovery paper set the template for the research that followed: a mitochondrial-encoded peptide with a proposed role in metabolic regulation, studied first in cells and mice.

The proposed mechanism

The mechanism most often attributed to MOTS-C in the literature is described by its authors as the folate-AICAR-AMPK pathway, and it is presented as proposed rather than settled.[1] In the 2015 study, the investigators reported that MOTS-C inhibited the folate cycle and the de novo purine biosynthesis tethered to it. They observed an associated accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), an intermediate that activates AMP-activated protein kinase (AMPK), a central regulator of cellular energy state.[1] The reported chain runs from folate-cycle inhibition to AICAR accumulation to AMPK activation.

A second feature appears in the later literature: retrograde signaling from the mitochondrion to the nucleus. In a 2023 review, MOTS-C is described as translocating to the nucleus under metabolic stress in an AMPK-dependent manner, where it is reported to associate with transcription-factor activity at antioxidant response elements and to influence the expression of stress-adaptation genes.[3] The 2021 Nature Communications work likewise reported that MOTS-C regulates nuclear genes involved in protein homeostasis.[4] Reviews describe this nuclear translocation as a proposed route by which a mitochondrially encoded peptide could shape nuclear gene expression.[3][5] These descriptions characterize a proposed mechanism observed in cell and animal systems, and not a confirmed pathway in humans.

What preclinical research has examined: metabolism and insulin sensitivity

Metabolism was the subject of the original 2015 report. In that study, the investigators examined MOTS-C in cell models (including HEK293, HeLa, and L6 myotubes) and in mice.[1] In mouse experiments using high-fat-diet feeding, the authors reported that administered MOTS-C was associated with reduced diet-induced obesity and with attenuation of high-fat-diet-induced and age-associated insulin resistance in those animals.[1] The reported effects were tied to the folate-AICAR-AMPK mechanism described above and to glucose handling in skeletal muscle.[1]

Subsequent reviews place these findings within a broader body of rodent and cell work on glucose metabolism. A 2023 review in the Diabetes & Metabolism Journal summarized MOTS-C research in the context of diabetes and aging-related conditions, noting reported associations between the peptide and insulin action across the cited animal and cell studies.[5] The consistent caveat across this literature is the model: the metabolic findings are observations in mice and cultured cells, and the reviews frame them as preclinical.

What preclinical research has examined: exercise and physical performance

The connection between MOTS-C and exercise was examined most directly by Reynolds, Lee, and colleagues in a 2021 Nature Communications study.[4] The authors reported that MOTS-C expression in skeletal muscle increased in response to exercise, characterizing it as an exercise-induced peptide.[4] The study spanned cell, animal, and limited human sampling: cultured myoblasts under metabolic stress, mice across young, middle-aged, and old groups, and human participants who provided blood and muscle samples during exercise protocols.[4]

In the mouse experiments, the investigators reported that administered MOTS-C was associated with improved performance on treadmill testing across the age groups studied, and they reported effects on muscle gene expression linked to protein homeostasis.[4] The human component of this study was an observational measurement of MOTS-C levels around exercise rather than a trial of the peptide as an intervention.[4] That distinction matters: the performance findings are mouse data, and the human data in the same paper describe the body's own MOTS-C responding to exercise rather than an administered dose producing an outcome in people.

What preclinical research has examined: aging

Aging is the third theme in the MOTS-C literature, and it is dominated by review articles rather than new human studies. A 2023 review in Frontiers in Endocrinology surveyed MOTS-C across metabolism and age-related conditions, describing it as a mitochondrial-derived peptide of interest for therapeutic exploration and summarizing the cell and animal findings reported to date.[3] A 2023 review in the Journal of Translational Medicine examined MOTS-C in relation to stress, metabolism, and aging, and restated the folate-AICAR-AMPK mechanism and the nuclear-translocation model drawn from the primary studies.[6] The Diabetes & Metabolism Journal review covered similar ground with a focus on diabetes and aging biology.[5]

These are observational syntheses of an existing preclinical literature. They aggregate what mouse and cell studies have reported and identify directions the authors consider worth investigating. None reports a completed human trial of MOTS-C as a therapy, and each frames the aging-related interest as hypothesis-generating.

The human-data status

The honest summary of the human evidence is short. There are no completed therapeutic human trials of MOTS-C itself. The peptide has not been approved by the FDA for any use.

The closest human exposure on record involves an analog rather than MOTS-C as discovered. CohBar, a company co-founded by MOTS-C discoverer Pinchas Cohen, developed CB-4211, described as a modified analog of MOTS-C, and advanced it into a Phase 1a/1b clinical study under development for nonalcoholic steatohepatitis (NASH) and obesity.[7] The company reported that CB-4211 was generally well tolerated, with the most common adverse events being transient, generally mild-to-moderate injection-site reactions; at one point the study was temporarily paused to address injection-site reactions described as unexpectedly persistent.[7] This was an early-phase safety and tolerability study of an analog rather than a late-stage efficacy trial of MOTS-C.

One further characterization belongs in any honest account: native MOTS-C is a circulating peptide that is not generally described as readily crossing the blood-brain barrier, which is part of why analog and delivery work has been pursued. The literature on central-nervous-system exposure is mixed and remains an open question rather than a settled fact. Taken together, the human-relevant picture is a single early-phase program on an analog, no approved product, and a body of mechanistic claims established in cells and mice.

How research-grade MOTS-C is characterized

Outside of clinical development, MOTS-C appears as a research-grade material, and the relevant context is analytical rather than therapeutic. A peptide supplied for laboratory work is characterized by its identity and its purity, established through defined analytical methods.

Identity is typically confirmed by mass spectrometry, which measures the molecular mass of the peptide and compares it against the expected value for the stated sequence. Purity is typically assessed by high-performance liquid chromatography (HPLC), which separates the components of a sample and reports the proportion attributable to the target peptide versus related impurities. Where this testing is performed by a laboratory accredited to the ISO/IEC 17025 standard, the resulting certificate of analysis reflects a defined competence and quality framework for the testing itself. These methods describe what a material is and how pure it is. They make no claim about what it does in a living system. The distinction is covered in more detail in companion pieces on how peptides are tested for purity and identity and on what an ISO 17025 certificate of analysis actually proves.

Regulatory status

MOTS-C is classified for research use and is not an FDA-approved drug for any indication. Its current regulatory posture sits inside the broader review of peptide compounding underway in the United States.

As a neutral matter of record, MOTS-C has appeared on the FDA's interim Category 2 list within the agency's framework for bulk drug substances nominated for use in compounding under Section 503A, the category for substances with potential concerns identified during interim review.[8] In April 2026 the FDA announced actions affecting the status of a group of peptides and scheduled a meeting of the Pharmacy Compounding Advisory Committee. On July 23 and 24, 2026, that committee is set to consider a number of peptide bulk drug substances, with MOTS-C (free base and acetate forms) among the substances on the agenda, under docket FDA-2025-N-6895.[8][9] The proceeding is documented further in a companion piece on the July 2026 PCAC meeting.

This regulatory activity is a description of process. A substance being scheduled for advisory-committee discussion is a procedural fact about an ongoing review. It does not by itself indicate approval, endorsement, or availability, and removal from one interim category does not by itself confer compounding eligibility.[8] FeelGood presents this status as a matter of record for readers tracking the regulatory landscape.

Frequently asked questions

What is MOTS-C?

MOTS-C is a mitochondrial-derived peptide of 16 amino acids, encoded by a short open reading frame within the 12S ribosomal RNA region (the MT-RNR1 gene) of mitochondrial DNA.[1] It was first described in a 2015 Cell Metabolism paper from a University of Southern California laboratory.[1] It belongs to a small family of peptides translated from the mitochondrial genome, alongside humanin, and most published research on it comes from cell and rodent studies.[1]

Is MOTS-C encoded by mitochondrial or nuclear DNA?

MOTS-C is encoded by mitochondrial DNA rather than the nuclear genome. Its coding sequence lies within the 12S ribosomal RNA region, the MT-RNR1 gene.[1] This places it among the mitochondrial-derived peptides, a class whose first described member, humanin, is encoded within a different mitochondrial ribosomal RNA region (MT-RNR2).[1] The mitochondrial origin is a defining feature of how this peptide family is studied.

Has MOTS-C been studied in humans?

There are no completed therapeutic human trials of MOTS-C itself, and it is not FDA-approved.[7] A 2021 study measured endogenous MOTS-C levels in human participants around exercise, an observational measurement rather than an intervention.[4] The nearest clinical exposure involved an analog, CB-4211, which entered a Phase 1a/1b study for NASH and obesity; the developer reported it was generally well tolerated, with transient injection-site reactions among the most common adverse events.[7]

What mechanism has preclinical research proposed for MOTS-C?

The mechanism most often reported is described by its authors as the folate-AICAR-AMPK pathway. In the 2015 discovery study, MOTS-C was reported to inhibit the folate cycle, leading to accumulation of the intermediate AICAR and subsequent activation of AMP-activated protein kinase (AMPK).[1] Later reviews describe MOTS-C translocating to the nucleus under metabolic stress in an AMPK-dependent manner, where it is reported to influence stress-adaptation gene expression.[3] These are proposed mechanisms observed in cell and animal systems.

What is the regulatory status of MOTS-C?

MOTS-C is classified for research use and is not an FDA-approved drug.[8] It has appeared on the FDA's interim Category 2 list within the Section 503A bulk-drug-substances framework, and the free-base and acetate forms are among substances scheduled for discussion at the Pharmacy Compounding Advisory Committee meeting on July 23 and 24, 2026, under docket FDA-2025-N-6895.[8][9] Scheduling for advisory-committee review is a procedural fact about an ongoing process and does not by itself indicate approval or availability.[8]

FeelGood supplies research-use-only peptides sourced in the United States and Europe. Each batch is released with a third-party certificate of analysis documenting identity by mass spectrometry, purity by high-performance liquid chromatography, and ISO 17025 accredited testing.

Footnotes

[1] Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism. 2015;21(3):443-454. PMID 25738459. PMCID PMC4350682. doi:10.1016/j.cmet.2015.02.009. https://pubmed.ncbi.nlm.nih.gov/25738459/

[2] The 16-amino-acid sequence MRWQEMGYIFYPRKLR is the sequence consistently reported for MOTS-C across the published literature. The 16-residue length and the 12S rRNA (MT-RNR1) encoding are documented in the discovery paper (see footnote 1) and in the review by Zheng Y, Wei Z, Wang T. "MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation." Frontiers in Endocrinology (Lausanne). 2023;14:1120533. PMID 36761202. PMCID PMC9905433. doi:10.3389/fendo.2023.1120533. https://pubmed.ncbi.nlm.nih.gov/36761202/

[3] Zheng Y, Wei Z, Wang T. "MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation." Frontiers in Endocrinology (Lausanne). 2023;14:1120533. PMID 36761202. PMCID PMC9905433. doi:10.3389/fendo.2023.1120533. https://pubmed.ncbi.nlm.nih.gov/36761202/

[4] Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C. "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." Nature Communications. 2021;12(1):470. PMID 33473109. PMCID PMC7817689. doi:10.1038/s41467-020-20790-0. https://pubmed.ncbi.nlm.nih.gov/33473109/

[5] Kong BS, Lee C, Cho YM. "Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases." Diabetes & Metabolism Journal. 2023;47(3):315-324. doi:10.4093/dmj.2022.0333. https://www.e-dmj.org/journal/view.php?number=2725

[6] Wan W, Zhang L, Lin Y, Rao X, Wang X, Hua F, Ying J. "Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging." Journal of Translational Medicine. 2023;21:36. PMID 36670507. doi:10.1186/s12967-023-03885-2. https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-023-03885-2

[7] CohBar, Inc. "CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity." Press release, August 10, 2021. https://www.globenewswire.com/news-release/2021/08/10/2278324/0/en/CohBar-Announces-Positive-Topline-Results-from-the-Phase-1a-1b-Study-of-CB4211-Under-Development-for-NASH-and-Obesity.html . The temporary pause to address persistent injection-site reactions is reported in CohBar, Inc. "CohBar Provides Update on CB4211 Clinical Trial," November 5, 2018. https://www.sec.gov/Archives/edgar/data/1522602/000121390018014875/f8k110518ex99-1_cohbar.htm

[8] U.S. Food and Drug Administration. "July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee." Advisory committee notice and agenda; bulk drug substances nominated for use in compounding under Section 503A; docket FDA-2025-N-6895. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

[9] U.S. Food and Drug Administration. Federal Register / regulations.gov, Docket No. FDA-2025-N-6895, announcing the July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting and the peptide bulk drug substances under consideration (MOTS-C free base and MOTS-C acetate among them). Published April 16, 2026. https://www.regulations.gov/docket/FDA-2025-N-6895